Shai Shimony
@ShaiShimony
Advanced clinical fellow @DanaFarber leukemia team. Taking care of people is not a job, it’s a passion and a way of living
ID:3501594983
31-08-2015 12:12:56
316 Tweets
178 Followers
180 Following
“Multilineage” vs “lymphoid-only” BCR::ABL1 involvement and distinct cooperating events determine gene expression in BCR::ABL1-positive ALL. ow.ly/3fLu50R8JAT #lymphoidneoplasia #clinicaltrialsandobservations
Why do Latino children have the highest risk for childhood leukemia in the US? We identify one cause for this in a paper out in Cell Genomics today, led by Adam de Smith, Lara Wahlster, Soyoung Elizabeth Jeon, Fulong Yu, Charleston Chiang, & colleagues:
cell.com/cell-genomics/…
What are the outcomes of patients with #BPDCN and AML treated with tagraxofusp combined with azacitidine & venetoclax?
Andy Lane (@DanaFarber) discusses the findings in a recent interview:
👉 ow.ly/RiGF50QStgy
#RareDisease #HemOnc #Hematology #ESHAL2024 ESH (Haematology)
We recently spoke with Andy Lane (@DanaFarber) at #ESHAL2024 to hear an update on the current treatment landscape for #BPDCN .
Click here to visit our site and watch the interview:
👉 ow.ly/2yka50QNJUh
#RareDisease #HemOnc #Hematology ESH (Haematology)
Important alert to all transplanters! Every #TransplantAllogeneic Doc who sees #MDSsm patients should read this paper by Coleman Lindsley !! Please do NOT decline to transplant otherwise eligible TP53-mut higher risk #MDSsm Pts who have donors ascopubs.org/doi/10.1200/JC…
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. pubmed.ncbi.nlm.nih.gov/38450850/ Five tables, 7 figures and 13 years of work summarized! #CMML #ASXL1 Mayo Clinic Comprehensive Cancer Center The Leukemia & Lymphoma Society AA&MDSIF
Sharing our latest work characterizing CHIP as a risk factor for acute kidney injury (AKI) using human cohort data and mouse models.
Published today in Nature Medicine:
nature.com/articles/s4159…
Maintenance treatment was safe, with low rates of infections and chronic GVHD, and minimal impact on T-cell immune reconstitution. ow.ly/NAUY50QHhfz #clinicaltrialsandobservations #transplantation
Just out in Journal of Clinical Oncology the VALDAC study of LDAC+Ven for MRD relapse or oligoblastic relapse in AML
MRD group: 46% MRD negativity
oligoblastic group: 73% CR/CRh/CRi
2 year OS 67% in MRD group, 53% in oligoblastic group
ascopubs.org/doi/10.1200/JC… Haematology Peter MacCallum CC & Royal Melbourne Peter Mac Research #leusm
Data from Maximilian Stahl featured in #ESHAL2024 provocative debate between Keith W Pratz MD and #AgnieszkaWierzbowska on whether VEN/AZA or intensive chemo is “best” in an #AML patient who goes to alloHSCT (IMHO, there is no answer: need ITT/ randomized data more focus on disease biology!)
Kicking off #ESHAL2024 with keynote lecture by Richard Stone from Dana-Farber helping hematologists find their way through the new WHO/ICC/ELN classifications and making the decision which clinical trial is right for their patients.
#ESHCONFERENCES #leusm